Drugs / DCR-AUD
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05845398 | Jan → Aug 2023 | alcohol-related disorders | Dicerna Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05021640 | Sep 2021 → Dec 2022 | alcohol-related disorders | Dicerna Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DCR-AUD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05845398 ↗ |
| Modality | Oligonucleotide (other) | “synthetic double-stranded (hybridized duplex) RNA oligonucleotide” NCT05845398 ↗ |
| Route | Subcutaneous | “Participant received a single dose of DCR-AUD 80 mg, subcutaneous injection on Day 1.” NCT05021640 ↗ |